阿奇霉素序贯疗法治疗小儿支原体肺炎临床疗效及安全性分析

Clinical efficacy and safety analysis of azithromycin sequential therapy in the treatment of mycoplasma pneumonia in children

目的:探讨阿奇霉素序贯疗法治疗小儿支原体肺炎临床疗效及安全性分析。方法:将2016年3月-2017年3月在我院儿科治疗的180例小儿支原体肺炎患儿随机分为两组,在常规止咳、退热、平喘等治疗的基础上,对照组采用红霉素治疗,观察组采用阿奇霉素序贯疗法治疗,比较两组患儿临床疗效、症状消失时间、不良反应。结果:观察组90例中,治愈43例,显效36例,有效10例,无效1例,总有效率为98.89%,对照组90例中,治愈36例,显效28例,有效13例,无效13例,总有效率为85.56%,观察组治疗总有效率明显高于对照组,两组间差异有统计学意义(P<0.05);观察组治疗后退热时间(3.1±0.8)d、咳嗽消失时间(3.7±0.5)d、肺部湿啰音消失时间(5.4±1.1)d,明显低于对照组的(4.6±0.7)d、(5.1±0.9)d、(7.2±1.4)d,两组间差异有统计学意义(P<0.05);观察组胃肠道不适、局部疼痛、皮疹、肝功能异常等不良反应明显低于对照组,两组间差异有统计学意义(P<0.05)。结论:阿奇霉素序贯疗法治疗小儿支原体肺炎疗效确切,利于症状的早期缓解,且能减少使用药量,降低不良反应发生率,具有积极的临床意义。

Objective： To explore the clinical efficacy and safety analysis of azithromycin sequential therapy in the treatment of mycoplasma pneumonia in children. Methods： 180 cases of children with mycoplasma pneumonia treated in our hospital from March 2016 to March 2017 were randomly divided into two groups. Based on the conventional relieving cough, fever, asthma and other basic treatment, the control group received erythromycin treatment, while the observation group received azithromycin sequential therapy. The clinical curative effect, symptoms disappearing time and adverse reactions in two groups were compared. Results： In 90 cases of the observation group, 43 cases were cured; 36 cases were significantly effective; 10 cases were effective; 1 case was ineffective; the effective rate was 98.89%; In 90 cases of the control group, 36 cases were cured; 28 cases were significantly effective; 13 cases were effective; 13 case were ineffective; the effective rate was 85.56%; the effective rate in the observation group was significantly higher than that in the control group; the difference was statistical significance （P〈0.05）. After the treatment, the cooling time in the observation group was （3.1±0.8） days, the disappearance time of cough was （3.7 ± 0.5） days, pulmonary rales disappearing time was （5.4± 1.1） days, which was significantly lower than （4.6± 0.7）, （5.1± 0.9） and （7.2 ± 1.4） days in the control group respectively; there were significant differences between groups （P〈0.05）; the gastrointestinal discomfort, pain, rash, abnormal liver fimction and other adverse reactions in the observation group were significantly lower than those in the control group; there were statistically significant differences between groups （P〈0.05）. Conclusion： Azithromycin sequential therapy had a significant effect in the treatment of mycoplasma pneumonia in children was beneficial[ to the early remission of symptoms, and could reduce the dosage and the incidence of adverse reactions, which was of positive clinical significanee.